Share

Huma Q. Rana

M.D., MPH

Clinical Director, Division of Cancer Genetics and Prevention

Senior Physician, Dana-Farber Cancer Institute

Assistant Professor of Medicine, Harvard Medical School

Huma Q. Rana, MD, MPH is the Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. At Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical management and the clinical operations that provide care to individuals with rare genetic susceptibilities to cancer. 

In addition to her clinical work, Dr. Rana leads multiple clinical research projects focused on developing cancer prevention and screening for those with hereditary cancer risk, and novel approaches to improving access to cancer genetics services. 

Dr. Rana received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her residencies in Internal Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai, and received her MPH from the Harvard T.H. Chan School of Public Health.  She has been a member of the Dana-Farber faculty since 2012.  

Huma Q. Rana

M.D., MPH

Clinical Director, Division of Cancer Genetics and Prevention

Senior Physician, Dana-Farber Cancer Institute

Assistant Professor of Medicine, Harvard Medical School

Huma Q. Rana, MD, MPH is the Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. At Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical management and the clinical operations that provide care to individuals with rare genetic susceptibilities to cancer. 

In addition to her clinical work, Dr. Rana leads multiple clinical research projects focused on developing cancer prevention and screening for those with hereditary cancer risk, and novel approaches to improving access to cancer genetics services. 

Dr. Rana received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her residencies in Internal Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai, and received her MPH from the Harvard T.H. Chan School of Public Health.  She has been a member of the Dana-Farber faculty since 2012.  

Recent Publications

Low allele frequency variants identified on germline multi-gene panel testing for cancer predisposition can suggest the presence of constitutional mosaicism

Published On 2025 Apr 22

Journal article

CONCLUSION: LAFVs were infrequently detected in MGPT, representing 0.8% of the total variants and 0.1% of total tested. Ancillary testing is needed to understand the origins and clinical implications of LAFVs in patients and families.


Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized Study

Published On 2025 Apr 10

Journal article

CONCLUSION: In this study, there was high acceptance of VE and it led to better GT uptake compared with the GC arm. However, it will be important for programs using VE to build-in more opportunities for patients to ask questions. Pretest VE is a viable option for patients with cancer who need their germline genetic test results to help guide surgical and medical decisions.